LGND News and Press, Ligand Pharmaceuticals Incorporated From 05/06/19

Novan to immediately receive $12 million of non-dilutive capital Ligand to receive milestones and tiered royalty for North America SB206 molluscum indication Phase 3 molluscum trial to begin recruitment of patients this month Molluscum top line results targeted early during the ...

Ligand Pharmaceuticals Inc. (LGND) Q1 2019 Earnings Conference Call May 2, 2019 4:30 PM ET Company Participants Todd Pettingill – Investor Relations John Higgins – Chief Executive Officer Matt Foehr – Chief Operating Officer Matt Korenberg – Chief Fi...

Ligand Pharmaceuticals (NASDAQ: LGND ): Q1 Non-GAAP EPS of $1.16; GAAP EPS of $31.32 beats by $1.43 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand management will host a conference call ...

Top-line data expected Q3 of 2019 Also reports recent results from clinician survey on radiocontrast agent selection and use Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal C...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call. Fir...

From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det...

The Ligand and SEEL Partnership On September 22, 2016, Ligand Pharmaceuticals Incorporated (LGND), a $2.6 Billion public company, announced the licensing of rights to four programs to Seelos Therapeutics, Inc. (SEEL), a newly formed company focused on the central nervous system. Accord...

ZULRESSO is the first and only treatment specifically indicated for postpartum depression Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of ...